Avadel Pharmaceuticals plc each representing one Ordinary Share (AVDL): Price and Financial Metrics
AVDL Price/Volume Stats
| Current price | $17.16 | 52-week high | $18.85 |
| Prev. close | $17.66 | 52-week low | $9.50 |
| Day low | $16.95 | Volume | 240,830 |
| Day high | $17.56 | Avg. volume | 1,212,414 |
| 50-day MA | $15.81 | Dividend yield | N/A |
| 200-day MA | $13.62 | Market Cap | 1.55B |
AVDL Stock Price Chart Interactive Chart >
Avadel Pharmaceuticals plc each representing one Ordinary Share (AVDL) Company Bio
Avadel Pharmaceuticals plc develops and commercializes pharmaceutical products based on its proprietary drug delivery technology for primary care and sterile injectable markets in the United States, France, and Ireland. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. The company was founded in 1990 and is based in Dublin, Ireland.
Latest AVDL News From Around the Web
Below are the latest news stories about AVADEL PHARMACEUTICALS PLC that investors may wish to consider to help them evaluate AVDL as an investment opportunity.
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q3 2023 Earnings Call TranscriptAvadel Pharmaceuticals plc (NASDAQ:AVDL) Q3 2023 Earnings Call Transcript November 8, 2023 Avadel Pharmaceuticals plc misses on earnings expectations. Reported EPS is $-0.41 EPS, expectations were $-0.35. Operator: Greetings, and welcome to the Avadel Pharmaceuticals Third Quarter 2023 Earnings Call. [Operator Instructions]. It is now my pleasure to introduce Austin Murtagh with Stern Investor Relations. […] |
Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results-- $7.0 million in third quarter LUMRYZ™ net revenue from U.S. commercial launch -- -- Generated robust demand for LUMRYZ with greater than 1,000 patients enrolled in RYZUPTM and more than 400 patients initiating therapy as of September 30 -- -- LUMRYZ to be added to preferred position for CVS commercial formularies effective January 1, 2024 -- -- Submitted sNDA for LUMRYZ in pediatric narcolepsy population on November 7th -- -- Management to host a conference call today at 8:30 a.m. ET -- DUBLI |
Avadel Pharmaceuticals to Present at Upcoming Investor ConferencesDUBLIN, Ireland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: Jefferies London Healthcare Conference: Fireside chat on Tuesday, November 14 at 5:00 p.m. GMT / 12:00 p.m. ET.Piper Sandler 35th Annual Healthcare Conference: Fireside chat on Wednesday, November 29 at 11:30 a.m. ET |
Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 8DUBLIN, Ireland, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 8, 2023, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2023. A live audio webcast of the call be accessed by visiting the investor relations secti |
Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) at World Sleep 2023– 17 abstracts accepted, including new and encore data emphasizing clinical benefit and patient preference for a once-at-bedtime narcolepsy treatment option – – Company to host symposium on October 24 with leading KOLs discussing evolution of the narcolepsy treatment landscape – DUBLIN, Ireland, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced new and encore data supporting the clinical pr |
AVDL Price Returns
| 1-mo | 5.67% |
| 3-mo | 24.08% |
| 6-mo | 74.57% |
| 1-year | 70.92% |
| 3-year | 108.76% |
| 5-year | 1,474.31% |
| YTD | 21.53% |
| 2023 | 97.21% |
| 2022 | -11.39% |
| 2021 | 20.96% |
| 2020 | -11.52% |
| 2019 | 192.64% |
Continue Researching AVDL
Want to see what other sources are saying about Avadel Pharmaceuticals Plc's financials and stock price? Try the links below:Avadel Pharmaceuticals Plc (AVDL) Stock Price | Nasdaq
Avadel Pharmaceuticals Plc (AVDL) Stock Quote, History and News - Yahoo Finance
Avadel Pharmaceuticals Plc (AVDL) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...